SCHEMBL727897

SCHEMBL727897

CC(C)Oc1ccc(N)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KMT2A Q03164 4/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
KDM4E B2RXH2 3/20 0.50
THRB P10828 2/20 0.50
RECQL P46063 2/20 0.50
CYP3A4 P08684 2/20 0.50
USP2 O75604 1/20 0.50
POLB P06746 1/20 0.50
PKM P14618 1/20 0.50
APEX1 P27695 1/20 0.50
BLM P54132 1/20 0.50
MCL1 Q07820 1/20 0.50
TNF P01375 1/20 0.50
HSPD1 P10809 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7904029 0.88 IRAK4 (0.50) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL30573224 0.86 ALDH1A1 (0.67) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL730026 0.86 ALDH1A1 (0.67) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL7564303 0.83 GAA (0.54) ALDH1A1MAPTKDM4EPOLBHPGD
SCHEMBL711082 0.82 ALDH1A1 (0.73) ALDH1A1KMT2AKDM4EPOLBMCL1
SCHEMBL12144981 0.82 ALOX5 (0.49) ALDH1A1KMT2AMEN1KDM4EIRAK4
SCHEMBL17908023 0.81 CSNK2A1 (0.52) ALDH1A1KMT2AIRAK4CFDXDH
SCHEMBL98371 0.80 ALDH1A1 (0.73) ALDH1A1KMT2AMAPTMEN1TDP1
SCHEMBL4430129 0.80 IRAK4 (0.54) ALDH1A1KMT2APOLBIRAK4XDH
SCHEMBL5863680 0.80 LMNA (0.49) ALDH1A1KMT2AMAPTMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101243043-B Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INT LTD 2013-03-20 CN claimed
EP-1910275-B1 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD NOGRA PHARMA LTD (IE) 2013-02-13 EP claimed
US-8138357-B2 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INTERNATIONAL LIMITED (IE) 2012-03-20 US claimed
US-20110152225-A1 PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants NOGRA PHARMA LIMITED (IE) 2011-06-23 US claimed
CN-101969943-A Compounds for the selective treatment of the intestinal immunoinflammatory component of celiac disease GIULIANI INT LTD 2011-02-09 CN claimed
US-20100305077-A1 COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE NOGRA PHARMA LIMITED (IE) 2010-12-02 US claimed
EP-2131829-A1 PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS Giuliani International Limited (IE) 2009-12-16 EP claimed
US-20090118357-A1 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INTERNATIONAL LIMITED (IE) 2009-05-07 US claimed
WO-2008104557-A1 PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS GIULIANI INTERNATIONAL LIMITED (IE) 2008-09-04 WO claimed
CN-101243043-A Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INT LTD (IE) 2008-08-13 CN claimed
US-8450506-B2 Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field NOGRA PHARMA LIMITED (IE) 2013-05-28 US disclosed
US-8450506-B2 Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field NOGRA PHARMA LIMITED (IE) 2013-05-28 US disclosed
US-8450506-B2 Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field NOGRA PHARMA LIMITED (IE) 2013-05-28 US disclosed
CN-101243043-B Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INT LTD 2013-03-20 CN disclosed
EP-1910275-B1 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD NOGRA PHARMA LTD (IE) 2013-02-13 EP disclosed
WO-2008104557-A1 PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS GIULIANI INTERNATIONAL LIMITED (IE) 2008-09-04 WO disclosed
CN-101243043-A Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INT LTD (IE) 2008-08-13 CN disclosed
EP-1910275-A2 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD Giuliani International Limited (IE) 2008-04-16 EP disclosed
WO-2007010514-A2 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD GIULIANI INTERNATIONAL LIMITED (IE) 2007-01-25 WO disclosed
WO-2007010514-A2 COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD GIULIANI INTERNATIONAL LIMITED (IE) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118357-A1 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field EGFR, ERBB3, FGFR3 ALDH1A1 2287/4885KMT2A 4440/4885MAPT 4833/4885
US-20100305077-A1 COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE SI, FABP2, NFKBIA ALDH1A1 2703/4885KMT2A 3932/4885MAPT 3002/4885
US-20110152225-A1 PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants PPARG, FABP2, PPARD ALDH1A1 983/4885KMT2A 4845/4885MAPT 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.